Maine Senator Olympia Snowe became the most-watched lawmaker in the U.S. healthcare debate by following one of the oldest and most pragmatic of maxims -- that all politics is local.
Democrats opened difficult talks on healthcare reform in the U.S. Senate Wednesday, promising to bridge party divisions on a government-run insurance plan and paying for the overhaul.
Abbott Laboratories Inc said its third-quarter profit rose 37 percent on strong demand for its Humira arthritis drug and nutritional products, as well as gains from a settlement with Medtronic Inc.
A key U.S. Senate committee endorsed a sweeping healthcare overhaul on Tuesday, gaining the support of an influential Republican and delivering President Barack Obama a victory on his top domestic priority.
Johnson & Johnson posted weaker-than-expected quarterly revenue on Tuesday as sales of prescription drugs and heart stents disappointed, sending its shares down 2.4 percent.
A key U.S. Senate committee endorsed a sweeping healthcare overhaul on Tuesday, gaining the support of an influential Republican and delivering President Barack Obama a victory on his top domestic priority.
Republican senator Olympia Snowe announced Tuesday that she will vote in favor of the Senate Finance Committee health care reform bill.
The Dow and S&P 500 fell on Tuesday after Johnson & Johnson reported disappointing third-quarter sales, while the Nasdaq edged up after Cisco Systems Inc announced a large acquisition.
Johnson & Johnson posted weaker-than-expected quarterly revenue on Tuesday as sales of prescription drugs and heart stents disappointed, sending its shares down 2.5 percent.
U.S. President Barack Obama's push for sweeping healthcare reform was poised to clear a key Senate hurdle on Tuesday, opening a new phase in the raging debate over his top domestic priority.
Stocks fell on Tuesday, threatening to break a six-day winning streak, as Johnson & Johnson's third-quarter sales figures disappointed investors.
Johnson & Johnson posted weaker-than-expected quarterly revenue on Tuesday as sales of prescription drugs and cardiac stents disappointed, sending its shares down more than 2 percent.
Johnson & Johnson posted weaker-than-expected quarterly revenue on Tuesday as sales of prescription drugs and cardiac stents disappointed, sending its shares down more than 2 percent.
Stock futures turned mostly lower on Tuesday as Johnson & Johnson's third-quarter sales figures disappointed investors, offsetting a lift from higher commodity prices that rose with the weaker U.S. dollar.
Stock futures were flat on Tuesday as a weaker U.S. dollar helped lift commodity prices and Johnson & Johnson's third-quarter sales figures disappointed investors.
Johnson & Johnson on Tuesday reported disappointing third-quarter sales on Tuesday, but beat earnings forecasts thanks to cost-cutting and raised its full-year profit forecast.
The U.S. Senate Finance Committee will vote on Tuesday on a bill to reform the U.S. healthcare system, President Barack Obama's main domestic objective.
* U.S. stock index futures rose slightly on Tuesday as investors awaited earning reports from Johnson & Johnson (JNJ.N) and Intel Corp (INTC.O).
Stock futures rose slightly on Tuesday as investors awaited earning reports from Johnson & Johnson and Intel Corp .
Britain's leading shares were 0.3 percent lower early on Tuesday, retreating from a 12-month high set the previous session with investors staying on the sidelines ahead of UK inflation data and upcoming U.S. corporate earnings.
The White House Monday blasted a report from the health insurance industry that said Senate healthcare legislation would lead to increases in annual insurance premiums of as much as $4,000 by 2019.
European stocks were up 1.2 percent by midday on Monday, hitting a near three-week high, as forecast-beating results from Philips (PHG.AS) fuelled hopes over results ahead of this week's earnings from bellwethers.
